First Tracks Biotherapeutics (TRAX) Corporate presentation summary

Strategic focus and pipeline overview

• Advancing differentiated antibody therapeutics for autoimmune and inflammatory diseases, prioritizing speed and capital efficiency.

• Lead program ANB033 (CD122 antagonist) targets multiple autoimmune indications, including celiac disease (CeD) and eosinophilic esophagitis (EoE).

• Rosnilimab (pathogenic T cell depleter) completed Phase 2b in rheumatoid arthritis (RA) with strong efficacy and safety.

• ANB101 (BDCA2 modulator) nearing completion of Phase 1 in healthy volunteers.

• $180 million cash position at launch, supporting a two-year cash runway.

ANB033 clinical and preclinical data

• Demonstrated favorable safety, tolerability, and pharmacokinetics in Phase 1a, with no serious adverse events or discontinuations.

• Achieved rapid, sustained reduction of pathogenic CD8+ T cells and NK cells, with effects limited to CD122-expressing cells.

• Preclinical models show significant survival benefit and reduced cytolytic gene expression in GVHD, and prevention of gluten-induced villous atrophy in CeD.

• Differentiated impact in CeD patient-derived PBMCs compared to competing anti-IL-15 and CD122 therapies.

• Phase 1b trials in CeD and EoE ongoing, with top-line data expected Q4 2026 (CeD) and mid-2027 (EoE).

Market opportunity and competitive landscape

• CeD: 2.1 million U.S. prevalence, 1.1 million diagnosed, ~250,000 non-responsive to gluten-free diet; $4-5B U.S. market potential.

• EoE: 340,000 diagnosed U.S. patients, 170,000 biologic-eligible, $5B+ U.S. sales anticipated by 2030.

• ANB033 targets both symptom and histology, differentiating from other therapies in development.

• Market expected to expand as new therapies address unmet needs in both responsive and newly diagnosed patients.